Diving into Batch-to-Batch Variability of Topical Products-a Regulatory Bottleneck.

PURPOSE: Following the recent European Medicine Agency (EMA) draft guideline on quality and equivalence of topical products, a modular framework for bioequivalence assessment is proposed, wherein the qualitative, quantitative, microstructure and product performance sameness is demanded to support generic applications. Strict regulatory limits are now imposed, but, the suitability of these limits has been subject of intense debate. In this context, this paper aims to address these issues by characterizing a panel of 8 reference blockbuster semisolid topical products. METHODS: For each product, three batches were selected and, whenever possible, batches retrieved from different manufacturing sites were considered. Product microstructure was evaluated in terms of globule size, pH, rheological attributes and, if required, the thermal behaviour was also assessed. Performance was evaluated through in vitro release testing (IVRT). Finally, an integrated multivariate analysis was performed to highlight the features that most contribute for product variability. RESULTS: Marked differences were registered within reference products. Statistical analysis demonstrated that if EMA criteria are applied, none of the same product batches can be considered as equivalent. Rheological parameters as well as IVRT indicators account for the majority of batch-to-batch differences. CONCLUSIONS: Semisolid dosage forms exhibit intrinsic variability. This calls for the attention to the need of establishing reasonable equivalence criteria applied to generic drug products. Graphical abstract.

Drilling into "Quality by Design" Approach for Analytical Methods.

The need for consistency in analytical method development reinforces the dependence of pharmaceutical product development and manufacturing on robust analytical data. The Analytical Quality by Design (AQbD), akin to the product Quality by Design (QbD) endows a high degree of confidence to the method quality developed. AQbD involves the definition of the analytical target profile as starting point, followed by the identification of critical method variables and critical analytical attributes, supported on risk assessment and design of experiment tools for the establishment of a method operable design region and control strategy of the method. This systematic approach moves away from reactive troubleshooting to proactive failure reduction. The objective of this review is to highlight the elements of the AQbD framework and provide an overview of their implementation status in various analytical methods used in the pharmaceutical field. These methodologies include but are not limited to, high-performance liquid chromatography, UV-Vis spectrophotometry, capillary electrophoresis, supercritical fluid chromatography, and high-performance thin-layer chromatography. Finally, a critical appraisal is provided to highlight how regulators have encouraged AQbD principles application to boost the prevention of method failures and a better understanding of the method operable design region (MODR) and control strategy, ultimately resulting in cost-effectiveness and regulatory flexibility.

Reconstructed Human Epidermis: An Alternative Approach for In Vitro Bioequivalence Testing of Topical Products.

The use of in vitro human skin permeation tests is of value when addressing the quality and equivalence of topical drug products in Europe and the US. Human skin is the membrane of choice for these studies. The use of human skin as a membrane is hindered by limited access, high variability of results, and limited applicability for drugs with low skin permeability. Reconstructed human epidermis (RhE) models are validated as skin surrogates for safety tests and have been explored for percutaneous absorption testing. Clotrimazole poorly permeates human skin and is widely available for topical treatments. In this study, clotrimazole creams were used to test the ability of RhE to be used as biological membrane for bioequivalence testing, based on the Draft Guideline on Quality and Equivalence of Topical Products (CHMP/QWP/708282/2018) using a discriminative and modified in vitro permeation test (IVPT). To fulfill the validation of a discriminatory method, Canesten® 10 mg/g cream was compared with a test product with the same drug strength, along with two "negative controls" dosed at a 50% and 200% drug strength. Products were compared in finite dose conditions, regarding maximal flux (Jmax) and the total amount of drug permeated (Atotal). The results showed the discriminatory power of the method among the three drug strengths with no interference of the placebo formulation. The study design and validation complied with the requirements established in the guideline for a valid IVPT. This new test system allowed for the equivalence comparison between test and comparator product. Higher permeability of the RhE compared to human skin could be observed. This arose as a strength of the model for this modified IVPT bioequivalence testing, since comparing permeation profiles among products is envisaged instead of drawing absolute conclusions on skin permeation extent. These results may support the acceptance of RhE as biological membranes for modified IVPT in bioequivalence testing of topical products.

Evaluation of chelating ion-exchange resins for separating Cr(III) from industrial effluents.

In this study two chelating resins containing iminodiacetic acid groups (Amberlite IRC 748 and Diaion CR 11) and a chelating resin based on sulfonic and diphosphonic acid groups (Diphonix) were investigated in order to separate Cr(III) from industrial effluents produced in hard and decorative electroplating. Samples of two industrial plants were characterized during a period of about one year and a half in terms of the metals content (Cr, Cu, Na, Ca, Fe and Ni), Total Suspended Solids (TSS), Total Dissolved Solids (TDS), Chemical Oxygen Demand (COD) and pH. Some of the physical properties of the resins, namely the moisture content, apparent density, intraparticle porosity and the particle size distribution were also evaluated. To quantify the sorption capacity of the resins, batch experiments were performed using synthetic solutions of Cr(III), as well as solutions of Fe in the case of Diphonix. The Langmuir and Langmuir-Freundlich isotherms enabled a good description of the ion-exchange equilibrium data, and the maximum sorption capacity determined for Amberlite and Diaion was 3.6 mequiv./g(dry resin). For Diphonix that parameter was 3.4 mequiv./g(dry resin). The Diphonix resin exhibits a high selectivity for transition metals (Fe, Ni) over the chromium trivalent. Therefore, it was screened as the most suitable for selectively removing those metal impurities from chromium electroplating effluents. For this resin, the sorption capacity is strongly dependent on the initial pH of the solution. Though, high regeneration efficiencies of Diphonix for stripping Cr(III) were found by using a mixture of NaOH/H(2)O(2). The mathematical model tested for describing the dynamics of the process allowed a good fitting to the experimental data and enabled the estimation of effective pore diffusivity of Cr(III). The saturations of Diphonix with industrial effluents demonstrated that the breakthrough capacity of the resin is affected by the presence of other species in solution, such as Fe and Ni. Nevertheless, these effluents may be treated with this resin, being possible to separate Cr(III) from other transition metallic ions in solution.